This is the authors' abstract. We don't add key points for this paper.
Background Tuberculosis (TB) in patients with haematological and solid malignancies is uncommon, and data on the impact of screening cancer patients for latent TB infection (LTBI) is limited. Recent European guidelines describing potential screening approaches prompted a review of TB cases at Barts Cancer Centre, a large specialist oncology centre, to identify the best screening strategy. Methods Positive Mycobacterium tuberculosis cultures and/or polymerase chain reaction (PCR) results from August 2017 to July 2023 were analysed, and electronic health records were reviewed to identify concomitant cancer diagnoses. Demographics, TB risk factors, clinical presentation, cancer treatment and outcomes were assessed. Results Sixteen patients with culture-confirmed TB were identified; seven pulmonary cases (of which two also had intrathoracic lymph node (LN) disease), four cases confined to intrathoracic lymph nodes, three disseminated, one pleural and one retropharyngeal with spinal disease. Five (31.3%) had undergone cancer chemotherapy reported to increase TB risk. None had a previous history of TB infection. TB contact was documented clearly in 12 cases of which three (18.8%), extra-pulmonary and disseminated cases, reported historical contact with a TB-infected individual. The median interval between cancer and TB diagnoses was 17 months. Among haematooncology patients; 5/7 (71.4%) developed TB within two months of starting cancer chemotherapy and 5/7 (71.4%) presented with persistent fever. Comparatively, 5/9 (55.6%) solid-oncology cases were incidentally identified through imaging. Conclusion This retrospective cohort study highlights the rarity of TB infection among cancer patients and identifies the challenges of risk-based screening. No universal risk factor was identified, while some patients lacked any apparent risk factors. These findings advocate for a pre-emptive approach to TB diagnosis, promoting early consideration of investigation of active TB following cancer chemotherapy initiation, particularly in patients with persistent fever and TB risk factors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ward et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: